Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies
Author:
Funder
National Medical Research Council Singapore
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Link
https://link.springer.com/content/pdf/10.1007/s11899-022-00679-z.pdf
Reference167 articles.
1. • Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen J, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saussele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84. https://doi.org/10.1038/s41375-020-0776-2. Outlines standard of care for patients with CML.
2. •• Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35. https://doi.org/10.1016/S1470-2045(10)70233-3S1470-2045(10)70233-3. Pivotal study demonstrating possibility of TFR.
3. • Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol. 2020;17(8):493–503. https://doi.org/10.1038/s41571-020-0367-1. Recent and comprehensive review on TFR.
4. Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009;16(2):122–31. https://doi.org/10.1177/107327480901600204.
5. Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, Altamura HK, Hiwase DK, Yeung DT, Kim DW, Branford S, Hughes TP. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. 2021;137(9):1196–207. https://doi.org/10.1182/blood.2020005514. Important study relating early BCR-ABL1 kinetics to distal TKI responses.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel targeted therapies in chronic myeloid leukemia;Pharmaceutical Science Advances;2024-09
2. Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities;Heliyon;2024-02
3. Exploring RAB11A Pathway to Hinder Chronic Myeloid Leukemia-Induced Angiogenesis In Vivo;Pharmaceutics;2023-02-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3